Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Particulate matter (PM) refers to a complex and variable mixture of tiny solid particles and liquid droplets suspended in air, originating from natural sources (such as dust, pollen, sea salt) and human activities (such as combustion, industrial processes, and vehicle emissions)[1][3][5][7][9]. PM is classified by aerodynamic diameter: **PM10** (<10 μm), **PM2.5** (<2.5 μm), and ultrafine particles (<0.1 μm[2]). These particles carry diverse chemicals, can penetrate deep into the lungs (PM2.5 and smaller), and are associated with a range of adverse health effects, including inflammation, cardiovascular and respiratory diseases, cancer (recognized as a Group 1 carcinogen), and neurodegenerative outcomes[3][6][8]. Particulate matter is regulated as a pollutant, not as a biological or pharmacological target; there are no direct pharmacological antagonists, and interventions focus on exposure reduction and public health monitoring rather than drug targeting of PM itself[6][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Particulate matter (PM).